Seminars in Oncology
Volume 30, Issue 1 , Pages 26-37 , February 2003

Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation

References 

  1. Curran WJ, Scott C, Langer C, et al.  Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol. 2000;19:484; (abstr 1891)
  2. Furuse K, Fukuoka M, Kawahara M, et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  3. Murray N, Coy P, Pater JL, et al.  Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11:336–344
  4. Turrisi AT, Kim K, Blum R, et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271
  5. Pignon JP, Arriagada R, Ihde DC, et al.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–1624
  6. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10:890–895
  7. Quon H, Shepherd FA, Payne DG, et al.  The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;43:39–45
  8. Yuen AR, Zou G, Turrisi AT, et al.  Similar outcome of elderly patients in Intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000;89:1953–1960
  9. Hill RP, Chambers AF, Ling V, et al.  Dynamic heterogeneity: Rapid generation of metastatic variants in mouse B16 melanoma cells. Science. 1984;224:998–1001
  10. Hill RP, Young SD, Ling V. Metastatic cell phenotypes: Quantitative studies using the experimental metastasis assay. Cancer Rev. 1986;5:118–151
  11. Claes T. Different susceptibilities of tumor cell subpopulations to cytotoxic agents and therapeutic consequences. In:  Owens AH,  Coffey DS,  Baylin SB editor. Tumor Cell Heterogeneity: Origins and Implications. New York, NY: Academic; 1982;p. 147–152
  12. Young RC. Drug resistance: The clinical problem. In:  Ozols RF editors. Drug Resistance in Cancer Therapy. Norwell, MA: Kluwer Academic; 1989;p. 1–5
  13. Cole SP, Bhardwaj G, Gerlach JH, et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650–1654
  14. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res. 1984;44:3643–3653
  15. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–1733
  16. Brodin O, Arnberg H, Bergh J, et al.  Increased radioresistance of an in vitro transformed human small cell lung cancer cell line. Lung Cancer. 1995;12:83–198
  17. Twentyman PR, Wright KA, Rhodes T. Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int J Radiat Oncol Biol Phys. 1991;20:217–220
  18. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  19. Trott KR. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys. 1990;19:1071–1075
  20. Hendry JH, Bentzen SM, Dale RG, et al.  A modeled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol. 1996;8:297–307
  21. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep. 1976;60:1749–1760
  22. Stephens TC, Steel GG. Regeneration of tumors after cytotoxic treatment. In:  Meyn RE,  Withers HR editor. Radiation Biology in Cancer Research. New York, NY: Raven; 1980;p. 385–395
  23. Cox JD, Pajak TF, Asbell S, et al.  Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1993;27:493–498
  24. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys. 2000;46:516–517
  25. Videtic GM, Fung K, Tomiak AT, et al.  Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer. 2001;33:249–258
  26. Jeremic B, Shibamoto Y, Acimovic L, et al.  Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol. 1997;15:893–900
  27. Takada M, Fukuoka M, Kawahara M, et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group study 9104. J Clin Oncol. 2002;20:3054–3060
  28. Takada M, Fukuoka M, Furuse K. Phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with cisplatin (C) and etoposide (E) for limited stage (LS) small-cell lung cancer. Proc Am Soc Clin Oncol. 1996;15:372; (abstr)
  29. Perry MC, Eaton WL, Propert KJ, et al.  Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 1987;316:912–918
  30. Perry MC, Herndon JE, Eaton WL, et al.  Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of Cancer and Leukemia Group B study 8083. J Clin Oncol. 1998;16:2466–2467
  31. Work E, Nielsen OS, Bentzen SM, et al.  Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol. 1997;15:3030–3037
  32. Skarlos DV, Samantas E, Briassoulis E, et al.  Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001;12:1231–1238
  33. Perez CA, Krauss S, Bartolucci AA, et al.  Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung: A randomized prospective study by the Southeastern Cancer Study Group. Cancer. 1981;47:2407–2413
  34. Belderbos JS, van Meerbeeck J, Weenink C. Concurrent chemo-radiation in small cell lung cancer (SCLC) LD; preliminary results from a Dutch pilot study. Lung Cancer. 2000;29(suppl 1, abstr 315):96
  35. Kies MS, Mira JG, Crowley JJ, et al.  Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: A Southwest Oncology Group study. J Clin Oncol. 1987;5:592–600
  36. Tada T, Minakuchi K, Koda M, et al.  Limited-stage small cell lung cancer: Local failure after chemotherapy and radiation therapy. Radiology. 1998;208:511–515
  37. Oda M, Tsuchiya R, Suzuki K, et al.  Patterns of failure in phase II trial of post-operative adjuvant cisplatin/etoposide (PE) in patients with completely resected stage I-IIIA small cell lung cancer (SCLC): The Japan Clinical Oncology Lung Cancer Study Group trial (JCOG9101). Proc Am Soc Clin Oncol. 2001;21:316a; (abstr 1259)
  38. White JE, Chen T, McCracken J, et al.  The influence of radiation therapy quality control on survival, response and sites of relapse in oat cell carcinoma of the lung: Preliminary report of a Southwest Oncology Group study. Cancer. 1982;50:1084–1090
  39. Arriagada R, Pellae-Cosset B, Ladron de Guevara JC, et al.  Alternating radiotherapy and chemotherapy schedules in limited small cell lung cancer: Analysis of local chest recurrences. Radiother Oncol. 1991;20:91–98
  40. Brodin O, Rikner G, Steinholtz L, et al.  Local failure in patients treated with radiotherapy and multidrug chemotherapy for small cell lung cancer. Acta Oncol. 1990;29:739–746
  41. McJury M, Fisher PM, Pledge S, et al.  The impact of virtual simulation in palliative radiotherapy for non-small-cell lung cancer. Radiother Oncol. 2001;59:311–318
  42. Graham MV, Purdy JA, Emami B, et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  43. Kwa SL, Lebesque JV, Theuws JC, et al.  Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9
  44. Tsujino K, Hirota S, Demizu Y, et al.  DVH analysis for predicting radiation pneumonitis in cases of advanced lung cancer treated with concurrent chemo-radiation. Int J Radiat Oncol Biol Phys. 2001;51(suppl 1, abstr 162):
  45. Graham MV, Purdy JA, Emami B, et al.  3-D conformal radiotherapy for lung cancer. The Washington University experience. Frontiers Radiat Ther Oncol. 1996;29:188–198
  46. Hirota S, Tsujino K, Endo M, et al.  Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys. 2001;51:291–295
  47. Lebeau B, Urban T, Brechot JM, et al.  A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. “Petites Cellules” Group. Cancer. 1999;86:1480–1487
  48. Arriagada R, Kramar A, Le Chevalier T, et al.  Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group. J Clin Oncol. 1992;10:447–451
  49. Coy P, Hodson I, Payne DG, et al.  The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian multicenter randomized trial. Int J Radiat Oncol Biol Phys. 1988;14:219–226
  50. Choi NC, Carey RW. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: An update. Int J Radiat Oncol Biol Phys. 1989;17:307–310
  51. Duchesne GM, Peacock JH, Steel GG. The acute in vitro and in vivo radiosensitivity of human lung tumour lines. Radiother Oncol. 1986;7:353–361
  52. Carmichael J, Degraff WG, Gamson J, et al.  Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol. 1989;25:527–534
  53. Brodin O, Lennartsson L, Nilsson S. Single-dose and fractionated irradiation of four human lung cancer cell lines in vitro. Acta Oncol. 1991;30:967–974
  54. Bonner JA, Sloan JA, Shanahan TG, et al.  Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17:2681–2691
  55. Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer—The time factor. Int J Radiat Oncol Biol Phys. 1997;39:831–836
  56. Pignon JP, Bourhis J, Domenge C, et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949–955
  57. Gregor A, Drings P, Burghouts J, et al.  Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: A European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group study. J Clin Oncol. 1997;15:2840–2849
  58. Anonymous . Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research. Lancet. 1996;348:1049–1054
  59. Cooper JS, Guo MD, Herskovic A, et al.  Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623–1627
  60. Keys HM, Bundy BN, Stehman FB, et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–1161
  61. Morris M, Eifel PJ, Lu J, et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143
  62. Rose PG, Bundy BN, Watkins EB, et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–1153

☆ Address reprint requests to Nevin Murray, MD, FRCPC, Clinical Professor of Medicine, University of British Columbia, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, Canada V5Z 4E6.

PII: S0093-7754(03)70040-2

doi: 10.1053/sonc.2003.50017

Seminars in Oncology
Volume 30, Issue 1 , Pages 26-37 , February 2003

Article Tools

* Image Usage & Resolution